Skip to search formSkip to main contentSkip to account menu

treprostinil diolamine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Introduction Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis… 
2018
2018
Pulmonary arterial hypertension (PAH) is a progressive condition that can lead to right ventricular failure and death… 
Review
2016
Review
2016
Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil… 
Review
2015
Review
2015
Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left… 
2014
2014
Pulmonary arterial hypertension (PAH) is a rare yet progressive and life-threatening condition that, despite the availability of… 
Review
2014
Review
2014
Introduction: This review summarizes current information on the first oral prostanoid approved for treatment of pulmonary… 
2013
2013
Abstract: Pulmonary arterial hypertension (PAH) is a progressive vascular disease that ultimately leads to right ventricular… 
2013
2013
Abstract: Treprostinil diolamine sustained release (UT-15C SR) is being evaluated as an oral therapy for pulmonary arterial… 
2013
2013
Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue currently being evaluated for the treatment of pulmonary… 
2013
2013
Abstract: Treprostinil, a stable prostacyclin analogue used in the treatment of pulmonary arterial hypertension, is in…